- Cyteir Therapeutics press release ( NASDAQ: CYT ): Q2 GAAP EPS of -$0.34.
- Cash and cash equivalents as of June 30, 2022 were $166.4 million.
For further details see:
Cyteir Therapeutics GAAP EPS of -$0.34For further details see:
Cyteir Therapeutics GAAP EPS of -$0.34Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Cyteir Therapeutics Inc. Company Name:
CYT Stock Symbol:
Market:
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...